IDH2 and acute myeloid leukemia: The Food and Drug Administration has recently approved Enasidenib, a specific molecular inhibitor for patients with AML with mutated IDH2. IDH2 is an enzyme that catalyzes the first oxidative decarboxylation reaction of the isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid cycle.